DE60128950D1 - Proteine aus yaba monkey tumor virus mit modulatorischer aktivität - Google Patents

Proteine aus yaba monkey tumor virus mit modulatorischer aktivität

Info

Publication number
DE60128950D1
DE60128950D1 DE60128950T DE60128950T DE60128950D1 DE 60128950 D1 DE60128950 D1 DE 60128950D1 DE 60128950 T DE60128950 T DE 60128950T DE 60128950 T DE60128950 T DE 60128950T DE 60128950 D1 DE60128950 D1 DE 60128950D1
Authority
DE
Germany
Prior art keywords
proteins
tumor virus
yaba monkey
monkey tumor
modulatory activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60128950T
Other languages
English (en)
Other versions
DE60128950T2 (de
Inventor
Grant Mcfadden
Alexandra Lucas
Xing Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viron Therapeutics Inc
Original Assignee
Viron Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viron Therapeutics Inc filed Critical Viron Therapeutics Inc
Application granted granted Critical
Publication of DE60128950D1 publication Critical patent/DE60128950D1/de
Publication of DE60128950T2 publication Critical patent/DE60128950T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
DE60128950T 2000-12-04 2001-12-04 Immunmodulatorisches Protein abgeleitet vom Yaba-Affentumor-Virus Expired - Lifetime DE60128950T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25114700P 2000-12-04 2000-12-04
US251147P 2000-12-04
PCT/CA2001/001734 WO2002046214A2 (en) 2000-12-04 2001-12-04 Immunomodulatory protein derived from the yaba monkey tumor virus

Publications (2)

Publication Number Publication Date
DE60128950D1 true DE60128950D1 (de) 2007-07-26
DE60128950T2 DE60128950T2 (de) 2008-02-28

Family

ID=22950675

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60128950T Expired - Lifetime DE60128950T2 (de) 2000-12-04 2001-12-04 Immunmodulatorisches Protein abgeleitet vom Yaba-Affentumor-Virus

Country Status (11)

Country Link
US (1) US7101559B2 (de)
EP (1) EP1339737B1 (de)
JP (3) JP4472252B2 (de)
AT (1) ATE364625T1 (de)
AU (2) AU2002215727B9 (de)
CA (1) CA2428097A1 (de)
DE (1) DE60128950T2 (de)
DK (1) DK1339737T3 (de)
ES (1) ES2287192T3 (de)
PT (1) PT1339737E (de)
WO (1) WO2002046214A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1174402A (en) 2000-10-11 2002-04-22 Viron Therapeutics Inc Nucleic acid molecules and polypeptides for immune modulation
DK1339737T3 (da) 2000-12-04 2007-10-15 Viron Therapeutics Inc Immunomodulatorisk protein dannet ud fra Yaba-abetumorvirus
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
US8251876B2 (en) 2008-04-22 2012-08-28 Hill-Rom Services, Inc. Breathing exercise apparatus
US9180271B2 (en) 2012-03-05 2015-11-10 Hill-Rom Services Pte. Ltd. Respiratory therapy device having standard and oscillatory PEP with nebulizer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US38203A (en) * 1863-04-14 Improved strike for door-locks
US5651972A (en) * 1989-04-21 1997-07-29 University Of Florida Research Foundation, Inc. Use of recombinant swine poxvirus as a live vaccine vector
AU646695B2 (en) 1990-04-09 1994-03-03 Immunex Corporation Isolated viral protein cytokine antagonists
CA2081309A1 (en) 1990-04-24 1991-10-25 Paul J. Zavodny Soluble, truncated gamma-interferon receptors
DE69430924T2 (de) * 1994-04-08 2003-02-27 Viron Therapeutics, Inc. Antirestenoses protein
US5656465A (en) * 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US5939525A (en) * 1995-03-27 1999-08-17 Viron Therapeutics, Inc. Methods of treating inflammation and compositions therefor
US6495515B1 (en) * 1995-04-19 2002-12-17 Viron Therapeutics, Inc. Chemokine binding protein and methods of use therefor
US5834419A (en) * 1995-04-19 1998-11-10 The John P. Robarts Institute Chemokine binding protein and methods of use therefor
NZ320889A (en) 1995-09-29 2000-09-29 Immunex Corp A p35 protein which binds to and inhibits chemokines
EP1034789A1 (de) * 1996-05-22 2000-09-13 University Of Alberta Typ-2 Chemokine-Bindende Proteine und Verfahren zu deren Verwendung
WO1997044054A2 (en) * 1996-05-22 1997-11-27 University Of Alberta Type-2 chemokine binding proteins and methods of use therefor
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
US6589933B1 (en) * 1999-04-02 2003-07-08 Viron Therapeutics, Inc. Myxoma chemokine binding protein
AU2001240109A1 (en) * 2000-03-07 2001-09-17 U.S. Army Medical Research Institute Of Infectious Diseases Dna vaccines against poxviruses
AU1174402A (en) * 2000-10-11 2002-04-22 Viron Therapeutics Inc Nucleic acid molecules and polypeptides for immune modulation
DK1339737T3 (da) 2000-12-04 2007-10-15 Viron Therapeutics Inc Immunomodulatorisk protein dannet ud fra Yaba-abetumorvirus

Also Published As

Publication number Publication date
AU2002215727B8 (en) 2008-02-21
EP1339737B1 (de) 2007-06-13
JP4472252B2 (ja) 2010-06-02
ATE364625T1 (de) 2007-07-15
JP2009227686A (ja) 2009-10-08
CA2428097A1 (en) 2002-06-13
US7101559B2 (en) 2006-09-05
US20040038203A1 (en) 2004-02-26
JP2010077136A (ja) 2010-04-08
WO2002046214A3 (en) 2002-09-26
AU2002215727B9 (en) 2008-02-21
WO2002046214A2 (en) 2002-06-13
ES2287192T3 (es) 2007-12-16
DE60128950T2 (de) 2008-02-28
EP1339737A2 (de) 2003-09-03
PT1339737E (pt) 2007-09-03
DK1339737T3 (da) 2007-10-15
JP2004522427A (ja) 2004-07-29
AU1572702A (en) 2002-06-18
AU2002215727B2 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
CY1116385T1 (el) Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
ATE360808T1 (de) Unabhängiges gerät zur extraktion, amplifikation und nachweis von nukleinsäuren
EP1436429A4 (de) Zielnukleinsäurekonstrukte und damit verbundene verwendungen
WO2003016499A3 (en) Combinatorial methods for inducing cancer cell death
DE69819124D1 (de) Lyophilisation von kultivierten, menschlichen zellen zur konservierung der rna und dna
NO20055838L (no) Aktive varianter av IL-18 bindende protein og medisinske anvendelser derav
WO2000053776A3 (en) Human kallikrein-like genes
DE60139544D1 (de) Veränderte, fluoreszierende proteine
EP1536006A4 (de) Krebsantigene und deren nutzung
WO2005000335A3 (en) Use of genes differentially expressed during aging of liver for treatment and diagnosis
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
DE69833876D1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
ATE364625T1 (de) Proteine aus yaba monkey tumor virus mit modulatorischer aktivität
WO2001040313A3 (en) Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
WO2005042719A3 (en) Methods for treating and preventing ischemia-reperfusion injury using rna interfering agents
WO2004070012A3 (en) Cell-killing molecules and methods of use thereof
DE60107888D1 (de) Beta-Interferon zur Behandlung von Immunerkrankungen
EP1409710A4 (de) Nukleinsäure und dieser entsprechendes, 161p5c5 genanntes, für die behandlung und den nachweis von krebs geeignetes protein
WO2004113386A3 (en) Modified hirudin proteins and t-cell epitopes in hirudin
AP2781A (en) Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechansim, from the use of these porteins or from the inhibition thereof
ATE255594T1 (de) Hepatitis b inhibitoren
NL1020885A1 (nl) Glutaminase, glutaminasegen, nieuw recombinant DNA en werkwijze voor de bereiding van glutaminase.
WO2000065063A3 (en) Nucleic acid vaccines against rickettsial diseases and methods of use
WO2002011549A3 (en) Treatment of mycobacterial infection

Legal Events

Date Code Title Description
8364 No opposition during term of opposition